
Altimmune (ALT) Stock Forecast & Price Target
Altimmune (ALT) Analyst Ratings
Bulls say
Altimmune is a late clinical-stage biopharmaceutical company focused on developing therapies for serious liver diseases. The company's key drug candidate pemvidutide has a balanced dual-action mechanism targeting glucagon and GLP-1 receptors for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). Altimmune's PERFORMA protocol, a multinational Phase 3 trial for MASH, has been submitted to the FDA and is aligned with EMA feedback, with a targeted initiation in the second half of 2026 and a 52-week readout in 2029, which could provide a positive data point for pemvidutide. The company also has plans to pursue additional indications for pemvidutide that leverage its unique clinical profile. Altimmune has a strong financial position with cash, equivalents, and short-term investments of $332 million as of March 2021 and a pro forma level of $535 million after successful stock offerings, providing a runway through the PERFORMA trial.
Bears say
Altimmune is a late clinical-stage biopharmaceutical company, with its leading candidate pemvidutide targeting multiple indications in the liver disease space. While the candidate has shown promise in early trials, the company faces strong competition in the market and limited financial resources for its development. Additionally, the recent dilution of shares following a financing round has lowered the potential for future returns and reduced our price target to $11.
This aggregate rating is based on analysts' research of Altimmune and is not a guaranteed prediction by Public.com or investment advice.
Altimmune (ALT) Analyst Forecast & Price Prediction
Start investing in Altimmune (ALT)
Order type
Buy in
Order amount
Est. shares
0 shares